A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.Michael J. Overman, Harold M. Wright, Lina Petrosyan et al.|Journal of Clinical Oncology|2023Cited by 18
[Corrigendum] 7‑Difluoromethoxyl‑5,4'‑di‑n‑octyl genistein inhibits the stem‑like characteristics of gastric cancer stem‑like cells and reverses the phenotype of epithelial‑mesenchymal transition in gastric cancer cellsXiaozheng Cao, Hui Zou, Kaiqun Ren et al.|Oncology Reports|2022Cited by 1